XIAMEN AMOYTOP BIOTECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 60.51 CNY | -0.31% |
|
-6.43% | +15.59% |
| Apr. 22 | Xiamen Amoytop Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 18 | China Stocks Advance Over Positive Economic Data; Amoytop Biotech Rises 6% | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
XIAMEN AMOYTOP BIOTECH CO., LTD is a China-based company mainly engaged in the biopharmaceutical business, including the research, development, manufacture and sales of recombinant proteins and their long-acting modified drugs. The Company's main research and development direction is immune-related cytokine drugs, focusing on systemic immune solutions based on cytokine drugs, and its products mainly include Peginterferon alfa-2b Injection, rhGM-CSF (Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection), rHuG-CSF (Recombinant Human Granulocyte-Colony Stimulating Factor for Injection) and Recombinant Human Interleukin-11 for Injection. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
60.51
CNY
Average target price
89.2
CNY
Spread / Average Target
+47.41%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +15.59% | 3.41B | |
| -3.45% | 87.17B | |
| +2.76% | 40.1B | |
| -16.37% | 31.38B | |
| +57.86% | 25.12B | |
| -16.09% | 15.59B | |
| -9.12% | 12B | |
| -42.56% | 11.8B | |
| -18.35% | 11.8B | |
| +6.89% | 8.81B |
- Stock Market
- Equities
- 688278 Stock
- News Xiamen Amoytop Biotech Co., Ltd.
- Xiamen Amoytop Biotech Gets Nod to Market Hepatitis Drug; Shares Up 4%
